This handbook is intended to help policymakers and practitioners incorporate the lessons learned from this preventable disaster to avert and/or mitigate future crises. Specifically, it provides guidance for implementing several key, overarching recommendations produced through extensive research and analysis aimed at answering the following key legal question with respect to the Flint water crisis: Given the emergency manager’s appointment, what legal authority could state, local, and federal public health and environmental agencies use to avert or mitigate the crisis?
This primer addresses the purpose of emergency manager laws; how they operate; the emergency manager’s powers, duties and limitations; the role of citizens and elected officials while under emergency management; transition after emergency management; and the intersection of emergency manager laws with other laws.
A new report released by the Network for Public Health Law and the University of Michigan School of Public Health details why shortcomings in the structure and implementation of laws related to public health, safe drinking water, and emergency financial management failed to stop or mitigate the Flint water crisis. Along with key findings, the report provides recommendations to help prevent similar crises from happening in other communities.
A requester contacted the Network noting that it is a misdemeanor for pharmacists to sell drug paraphernalia in his state and that there were also no needle exchange sites in the state. Limited access to drug paraphernalia may increase the likelihood that intravenous drug users will share needles, increasing the spread of diseases like HIV and hepatitis C. The requester wanted to know if other states have similar laws and what strategies for harm reduction have been used in those states.
A policy analyst for a local health district contacted the Network for assistance in researching model health resolutions. Reviewing examples of resolutions is an excellent way for local boards of health and local governments to benefit from the knowledge and experience of other communities and public health leaders. In the course of the Network’s research to collect sample resolutions, several categories of resolutions emerged.
This Primer on Opioid-related Public Health Emergencies provides key information and visual snapshots of federal, state, tribal, and local emergency declarations in response to the opioid crisis across the U.S.
In the rapidly shifting contours of the opioid crisis, it is vital that governments, clinicians and the public have access to timely, comprehensive data on overdose deaths. Unfortunately, such data are rarely available. A handful of states have established bodies that specifically review overdose deaths to provide additional data and, typically, make recommendations for policy improvements. This brief explains and contrasts the specifics of panels in the six states that have established them.
Despite drastic expansion of marijuana legalization throughout U.S. states in recent years, federal guidance issued in January 2018 is at odds with this movement, imparting legal uncertainty on the future of the marijuana industry. This Issue Brief reviews the current federal legal framework regarding marijuana control and explores possible options for federal, state, and local governments in the near future.
High rates of morbidity and mortality among Americans related to opioid use have lead multiple jurisdictions to declare a formal state of emergency and public health emergency. Declaring a state of emergency grants states and localities additional resources to address the epidemic immediately. This Fact Sheet provides a brief summary of the emergency declarations in six states, and the Primer provides a visual snapshot and synopses of state-and tribal-based emergency declarations across the U.S. based on currently-available information.
Some local and municipal governments have enacted mandatory local drug take-back programs, also called Extended Producer Responsibility (EPR) or stewardship programs that are funded and managed by pharmaceutical companies or producers. This issue brief provides and overview of mandatory drug take-back programs in the U.S.